# Pulmonology Consultation

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Leonard Nimoy (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML017-SYN-TD
- Date: 2014-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Owen Rasmussen, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

- Requested by: Carla Benedetti, MD

## Reason for consultation

COPD in an 82-year-old former smoker, now confirmed on spirometry as GOLD 3. Please confirm the grade and group, review the inhaler choice and the place of an inhaled corticosteroid, assess his oxygen needs, and advise on pulmonary rehabilitation and lung cancer screening. **S**

## History

Mr. Nimoy is seen at the request of Dr. Benedetti four weeks after starting tiotropium-olodaterol. He smoked heavily for many years, quit about 30 years ago through a cessation program, and has been limited by breathlessness for some time. He now stops after about 100 meters on level ground. His mornings are a little easier on the new inhaler, and his albuterol use has fallen to about four times a week. He has little cough, a small amount of clear morning sputum, and no wheeze at rest, chest pain, orthopnea, ankle swelling, snoring, or reflux. He has had no exacerbation in the past year. He is keen to keep active and to warn others about smoking. **S**

## Examination

| System | Finding |
|---|---|
| General | Tall man, comfortable at rest, speaking in full sentences |
| Chest | Hyperinflated; reduced breath sounds throughout with prolonged expiration; no wheeze or crackles |
| Cardiovascular | Regular rhythm; no murmur; no raised jugular venous pressure or edema |
| Extremities | No clubbing or cyanosis |
| Inhaler technique | Correct with the soft mist inhaler |

BP 128/76 mmHg; pulse 82 bpm; respirations 18/min; temperature 36.6 °C; oxygen saturation 93% on room air; weight 80.2 kg; BMI 23.4 kg/m². All vital signs are synthetic.

## Data reviewed

Intake spirometry before and after bronchodilator, the blood eosinophil count, the alpha-1 antitrypsin level, hemoglobin, creatinine, the intake ECG, the CAT and mMRC scores, and today's 6-minute walk test with continuous oximetry. 6-minute walk distance: 270 m (low). All results are synthetic.

## Assessment

1. **COPD, GOLD 3, group B** (J44.9). Confirmed: post-bronchodilator FEV1/FVC 0.43 with FEV1 46 percent predicted is GOLD grade 3. CAT 19 today (22 at intake), mMRC 3, and no exacerbation in 12 months place him in group B. Normal hemoglobin, a normal ECG, and no signs of heart failure make another main cause of his breathlessness unlikely. **S**
2. **Oxygen assessment**. Resting saturation 93 percent. On the 6-minute walk he covered 270 m with a lowest saturation of 89 percent. He meets no criterion for long-term oxygen, and the evidence does not support oxygen for moderate exertional desaturation; an arterial blood gas is not needed while resting saturation stays above 92 percent. **S**
3. **Alpha-1 antitrypsin and imaging**. 138 mg/dL is normal, which excludes severe deficiency; no phenotyping is needed. He is not eligible for lung cancer screening, because he quit more than 15 years ago. Chest CT is not needed now: there is no suspected complication, and lung volume reduction would only be considered if he stayed severely limited after optimal treatment and rehabilitation. **S**

## Recommendations

1. Continue tiotropium-olodaterol two inhalations each morning, with albuterol as needed; the soft mist inhaler suits him because it needs no strong inspiratory effort.
2. No inhaled corticosteroid: he has had no exacerbation and his eosinophils are below 300 per microliter. Reconsider after two moderate exacerbations or one hospital stay in a year if eosinophils are 100 or more.
3. Pulmonary rehabilitation now, with a 6-minute walk at entry (done today) and at exit.
4. No oxygen; check saturation at every visit and reassess if resting saturation falls to 92 percent or less.
5. No further alpha-1 antitrypsin testing and no chest CT at present.
6. PCV20 now, RSV vaccine before the next respiratory virus season, and yearly high-dose influenza and COVID-19 vaccines.
7. Written action plan for flare-ups; spirometry yearly.

## Strengths and supports

- Supports: spouse, adult children, long-time friends and colleagues; wants to use his experience to persuade smokers to quit **S**

## Communication

Discussed with Dr. Benedetti the same day; the patient agrees with the plan. **S**

## Follow-up

Primary care will continue monitoring on the CMID schedule. Pulmonology will see him again after any hospital stay for an exacerbation, two or more moderate exacerbations in a year, a fall in resting saturation to 92 percent or less, or loss of the benefit from rehabilitation. **S**

## Guideline basis

- Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 report (2025), Global Initiative for Chronic Obstructive Lung Disease
- CMID: Clinical Monitoring Intelligence Database, chronic obstructive pulmonary disease monograph (2026), Aether Forge
- Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023), American Thoracic Society (Am J Respir Crit Care Med 2023;208(4):e7-e26)
- Home Oxygen Therapy for Adults with Chronic Lung Disease: An Official American Thoracic Society Clinical Practice Guideline (2020), American Thoracic Society (Am J Respir Crit Care Med 2020;202(10):e121-e141)
- Lung Cancer: Screening (2021), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Age (2026), Centers for Disease Control and Prevention
